Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis00:59

Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis

Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Nonlinear Pharmacokinetics: Overview01:19

Nonlinear Pharmacokinetics: Overview

Nonlinear or dose-dependent pharmacokinetics is a phenomenon that occurs when the pharmacokinetic parameters of certain drugs deviate from linear pharmacokinetics at higher doses. These drugs do not follow the expected first-order kinetics, where the rate of drug elimination is directly proportional to the drug concentration. Instead, they exhibit a nonlinear relationship, which can be attributed to several factors.
Nonlinearity can arise due to the saturation of plasma protein-binding or...
Nonlinear Pharmacokinetics: Causes of Nonlinearity01:22

Nonlinear Pharmacokinetics: Causes of Nonlinearity

Nonlinearity in drug pharmacokinetics is caused by various factors influencing how a drug is absorbed, distributed, metabolized, and excreted. Understanding these nonlinear processes is crucial for predicting drug behavior in the body and optimizing drug dosing regimens.
Nonlinear drug absorption can occur when the process is rate-limited by solubility, carrier-mediated transport systems, or saturation of the presystemic gut wall or hepatic metabolism. For instance, high doses of riboflavin...
Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding01:22

Nonlinear Pharmacokinetics: Bioavailability and Protein-Drug Binding

When a drug follows nonlinear pharmacokinetics, its bioavailability, the amount of the drug that reaches the systemic circulation, can change with different doses. This is due to the presence of a saturable pathway. The pathway becomes saturated as the drug concentration increases, decreasing the absorption rate. Consequently, the drug's bioavailability may be lower than expected at higher doses.
To quantify the extent of bioavailability, pharmacologists often use a parameter called .

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Every 36-h gentamicin dosing in neonates with hypoxic-ischemic encephalopathy receiving hypothermia.

Journal of perinatology : official journal of the California Perinatal Association·2013
Same author

Population analyses of atorvastatin clearance in patients living in the community and in nursing homes.

Clinical pharmacology and therapeutics·2009
Same author

Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects.

British journal of clinical pharmacology·2005
Same author

Selecting reliable pharmacokinetic data for explanatory analyses of clinical trials in the presence of possible noncompliance.

Journal of pharmacokinetics and pharmacodynamics·2001
Same author

A semiparametric deconvolution model to establish in vivo-in vitro correlation applied to OROS oxybutynin.

Journal of pharmaceutical sciences·2001
Same author

Nasal mucosal versus gastrointestinal absorption of nasally administered cocaine.

European journal of clinical pharmacology·2000
Same journal

Correction.

Journal of biopharmaceutical statistics·2026
Same journal

Leveraging external controls in clinical trials: estimands, estimation, assumptions.

Journal of biopharmaceutical statistics·2026
Same journal

Special issue of nonclinical statistics in regulatory applications guest editors' notes.

Journal of biopharmaceutical statistics·2026
Same journal

Comparison of flexible parametric modeling and nonparametric methods to estimate restricted mean survival time: A simulation study.

Journal of biopharmaceutical statistics·2026
Same journal

Simulated treatment comparisons with jackknife pseudo values for estimating population-adjusted marginal treatment effects.

Journal of biopharmaceutical statistics·2026
Same journal

Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes.

Journal of biopharmaceutical statistics·2026
See all related articles

Related Experiment Video

Updated: Jun 29, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Linear mixed-effect multivariate adaptive regression splines applied to nonlinear pharmacokinetics data.

J M Gries1, D Verotta

  • 1Department of Biopharmaceutical Sciences, School of Pharmacy, University of California-San Francisco, 94143, USA.

Journal of Biopharmaceutical Statistics
|August 26, 2000
PubMed
Summary
This summary is machine-generated.

This study introduces a new method for analyzing drug concentration data in pharmacokinetics. It accurately models drug behavior over time and dose, identifying linear or nonlinear relationships without prior assumptions.

More Related Videos

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

A Workflow for Lipid Nanoparticle (LNP) Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models (SVEM)
13:54

A Workflow for Lipid Nanoparticle (LNP) Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models (SVEM)

Published on: August 18, 2023

Related Experiment Videos

Last Updated: Jun 29, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach
04:35

Development of an Individual-Tree Basal Area Increment Model using a Linear Mixed-Effects Approach

Published on: July 3, 2020

A Workflow for Lipid Nanoparticle (LNP) Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models (SVEM)
13:54

A Workflow for Lipid Nanoparticle (LNP) Formulation Optimization using Designed Mixture-Process Experiments and Self-Validated Ensemble Models (SVEM)

Published on: August 18, 2023

Area of Science:

  • Pharmacokinetics and Pharmacodynamics
  • Statistical Modeling
  • Biostatistics

Background:

  • Pharmacokinetics (PK) studies frequently involve administering varying drug doses to subjects and observing concentrations over time.
  • Determining the dose-concentration relationship and its linearity is crucial for understanding drug behavior.
  • Existing methods may impose assumptions on underlying PK or struggle with repeated measures and nonlinearity detection.

Purpose of the Study:

  • To develop a flexible model for drug concentration as a function of time and dose.
  • To create a method that makes no prior assumptions about drug pharmacokinetics.
  • To account for the repeated measures inherent in PK data and detect nonlinear dose-concentration relationships.

Main Methods:

  • Utilized Multivariate Adaptive Regression Splines (MARS) for flexible representation.
  • Integrated MARS into a linear mixed-effects model to handle repeated measures.
  • Developed an algorithm for nested MARS representations to detect nonlinearity.

Main Results:

  • The algorithm successfully generated representations of drug concentration based on time and dose.
  • Nested MARS representations allowed for the comparison of models linear versus nonlinear in dose.
  • Standard statistical criteria were employed for model selection, identifying the most appropriate representation.

Conclusions:

  • The proposed methodology offers a robust approach to modeling pharmacokinetics and pharmacodynamics.
  • It effectively handles complex data structures and identifies dose-dependent relationships.
  • This flexible method is applicable across various stages of drug development, from preclinical to clinical trials.